Zydus gets USFDA nod for blood pressure injection

Published On 2022-07-22 11:35 GMT   |   Update On 2022-07-22 11:35 GMT

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), has announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to market Norepinephrine Bitartrate Injection USP,4 mg/4 mL (1 mg/mL) Single-Dose Vial.Norepinephrine Bitartrate is indicated for restoration of blood pressure in adult patients with acute...

Login or Register to read the full article

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), has announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to market Norepinephrine Bitartrate Injection USP,4 mg/4 mL (1 mg/mL) Single-Dose Vial.

Norepinephrine Bitartrate is indicated for restoration of blood pressure in adult patients with acute hypotensive state.

For more details, check out the full story on the link below:

Zydus Lifesciences Bags USFDA Okay For Norepinephrine Bitartrate Injection


Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News